Walker, S <br/><br/>
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.  [electronic resource] 

 -  Health technology assessment (Winchester, England)  May 2011 
 - 13-21 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>2046-4924 
<br/><br/><label>Standard No.: </label>10.3310/hta15suppl1/02  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anti-Asthmatic Agents--administration & dosage<br/>Antibodies, Anti-Idiotypic--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Asthma--drug therapy<br/>Child<br/>Cost-Benefit Analysis<br/>Drug Therapy, Combination<br/>Glucocorticoids--therapeutic use<br/>Humans<br/>Models, Economic<br/>Multicenter Studies as Topic<br/>Omalizumab<br/>Quality of Life<br/>Quality-Adjusted Life Years<br/>Randomized Controlled Trials as Topic<br/>Severity of Illness Index